Trial reportAmerican journal of respiratory and critical care medicine2023
A Randomized Trial of Mesenchymal Stromal Cells for Moderate to Severe Acute Respiratory Distress Syndrome from COVID-19.
Open access · hybridAbstract readRandomized Controlled Trial
In one paragraph
Trial report in American journal of respiratory and critical care medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 6 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 6 pooled it
9.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 6 syntheses or guidelines pooled it, 63 citations in OpenAlex.
- Therapeutic potential of mesenchymal stromal cells in COVID-19: a meta-analysis of clinical trials conducted since the pandemic onset.Stem cell research & therapy · 2026Pooled it
- Efficacy and safety of mesenchymal stem/stromal cells and their derived extracellular vesicles for acute respiratory distress syndrome: a systematic review and meta-analysis.Stem cell research & therapy · 2025Pooled it
- Efficacy and safety of stem cell therapy vs. standard of care in patients diagnosed with acute respiratory distress syndrome: an updated systematic review and meta-analysis of randomized controlled trials.Frontiers in medicine · 2025Pooled it
- Efficacy and safety of mesenchymal stem cells therapy in COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials.Journal of translational medicine · 2024Pooled it
- Mesenchymal Stem Cells on Mortality in COVID-19 Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Stem cell reviews and reports · 2024Pooled it
- The safety and efficacy of mesenchymal stromal cells in ARDS: a meta-analysis of randomized controlled trials.Critical care (London, England) · 2023Pooled it
- Cellular immunotherapy for COVID-19-induced acute respiratory distress syndrome: Results of the CIRCA-19 phase 1 safety and phase 2 randomized controlled trials.Stem cell reports · 2026Trial
- Long-term outcomes of mesenchymal stem cell therapy in severe COVID-19 patients: 3-year follow-up of a randomized, double-blind, placebo-controlled trial.Stem cell research & therapy · 2025Trial
- Randomized, double-blinded, placebo-controlled trial of allogeneic cord blood T-regulatory cells for treatment of COVID-19 ARDS.Blood advances · 2023Trial
- The Acute Respiratory Distress Syndrome (ARDS): epidemiology, etiology, molecular mechanisms, diagnosis and therapeutic strategies.Molecular biomedicine · 2026Review
- Genetically Modified MSCs for Targeted Regeneration: Balancing Efficacy, Biosafety, and GMP Standardization.Cells · 2026Review
- Bone Marrow Mesenchymal Stem Cell Extracellular Vesicle Treatment of Respiratory Failure from COVID-19: Endpoint Analysis of Expanded Access Safety Trial.Stem cell reviews and reports · 2026Article
- The PPARβ/Delta-Induced Mesenchymal Stromal Cell Secretome Has Cytoprotective Effects via ANGPTL4 in a Pre-Clinical Model of Acute Lung Inflammation.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Designs of the clinical trials aiming at evaluating cell and gene therapy products: A critical appraisal from a literature review.Molecular therapy. Advances · 2026Review
- Scaling the manufacture of adipose tissue-derived mesenchymal stromal cells: integrated bioreactor workflows from inoculation to harvest without the need of seed train.BMC biotechnology · 2026Article
- Pulmonary vascular dysfunction in ARDS Pathophysiology and therapeutic implications.Annals of intensive care · 2026Review
- Mesenchymal stem cells and derived extracellular vesicles in major respiratory diseases: from multifaceted molecular mechanisms to clinical perspectives.Frontiers in cell and developmental biology · 2026Review
- Safety and efficacy of human umbilical cord-derived mesenchymal stem cells in COVID-19 patients: A real-world observation.Chinese medical journal · 2025Observational
- From development to regeneration: the endothelial interface in lung injury and repair.American journal of physiology. Lung cellular and molecular physiology · 2025Review
- Differential Phase Contrast Imaging to Predict MSC Immune Function.Advanced healthcare materials · 2025Article
Corrections and comments
- Commented on by
Authors and funding
37 authors at 18 institutions in 3 countries.
Michael E BowdishDepartment of Surgery and Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California.ORCID 0000-0002-0863-2825
Christina E BarkauskasDivisions of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine and.ORCID 0000-0001-8793-9050
Jessica R OverbeyPopulation Health Science and Policy, and.ORCID 0000-0001-7283-1661
Robert L GottliebAdvanced Heart Failure and Transplant Cardiology and.ORCID 0000-0001-8376-8709
Keren OsmanThe Tisch Cancer Institute, Icahn School of Medicine, New York, New York.
Abhijit DuggalDepartment of Critical Care, Respiratory Institute and.ORCID 0000-0003-4220-2359
Mary E MarksPopulation Health Science and Policy, and.
Jonathan HupfPopulation Health Science and Policy, and.
Eustace FernandesPulmonology, Lutheran Medical Group, Fort Wayne, Indiana.
Bradley G LeshnowerCardiothoracic Surgery, Emory University School of Medicine, Atlanta, Georgia.
Jonathan L GolobDivision of Infectious Diseases, Department of Medicine and.ORCID 0000-0003-0009-5815
Alexander IribarneSection of Cardiac Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.ORCID 0000-0001-5939-564X
Athos J RassiasSection of Cardiac Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.
Ellen G MoquetePopulation Health Science and Policy, and.
Karen O'SullivanPopulation Health Science and Policy, and.
Helena L ChangPopulation Health Science and Policy, and.
Judson B WilliamsCardiovascular Surgery, WakeMed Health and Hospitals, Raleigh, North Carolina.
Sam ParniaDepartment of Medicine, New York University Grossman School of Medicine, New York, New York.ORCID 0000-0002-6158-4404
Nirav C PatelDepartment of Cardiothoracic Surgery, Northwell Health, Manhasset, New York.
Nimesh D DesaiCardiac Surgery, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
Andrew M VeksteinDivision of Cardiovascular and Thoracic Surgery, Department of Surgery, Duke University, Durham, North Carolina.ORCID 0000-0002-8752-6632
Beth A HollisterDivision of Cardiovascular and Thoracic Surgery, Department of Surgery, Duke University, Durham, North Carolina.
Tammie PossematoDepartment of Surgery and Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California.ORCID 0000-0003-2163-9113
Christian RomeroDepartment of Surgery and Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California.
Peter C HouDivision of Emergency Critical Care Medicine, Department of Emergency Medicine and.ORCID 0000-0002-7726-2901
Elizabeth BurkeMesoblast, Inc., New York, New York.
Jack HayesMesoblast, Inc., New York, New York.
Fred GrossmanMesoblast, Inc., New York, New York.
Silviu ItescuMesoblast, Inc., New York, New York.
Marc GillinovDepartment of Thoracic & Cardiovascular Surgery, Cleveland Clinic, Cleveland, Ohio.
Francis D PaganiCardiac Surgery, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0003-4430-9969
Patrick T O'GaraCardiovascular Medicine, Brigham and Women's Hospital, Boston, Massachusetts; and.ORCID 0000-0003-0601-1088
Michael J MackCardiac and Thoracic Surgery, Baylor Scott & White Health, Dallas, Texas.
Peter K SmithDivision of Cardiovascular and Thoracic Surgery, Department of Surgery, Duke University, Durham, North Carolina.
Emilia BagiellaPopulation Health Science and Policy, and.
Alan J MoskowitzPopulation Health Science and Policy, and.ORCID 0000-0002-4412-9450
Annetine C GelijnsPopulation Health Science and Policy, and.ORCID 0000-0001-5389-953X
Institute of Population and Public Health · CAMesoblast (United States) · USDuke University · USUniversity of Southern California · USDartmouth–Hitchcock Medical Center · USUniversity of Michigan · USBaylor Scott & White Health · USBrigham and Women's Hospital · USCleveland Clinic · USEmory University · USHospital of the University of Pennsylvania · USInstitute for Respiratory Health · AULutheran Medical Group · USNew York University · USNorthwell Health · USPulmonary and Allergy Associates · USTisch Hospital · USWakeMed · US
Funding
REVISED CAROL ACT IIU01HL088942 · NHLBI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GELIJNS, ANNE CHRISTINE, MOSKOWITZ, ALAN J · 2007 to 2025
$122.6MNHLBI NIH HHS U01 HL088942
Abstract
PubMed holds no abstract for this paper.
Indexed as
COVID-19Mesenchymal Stem CellsRespiratory Distress SyndromeHumansLungSARS-CoV-2clinical trialmechanical ventilationSARS-CoV-2stem cellssurvival
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.